If the true measure of a company’s strength is whether customers come back again, then Glac Biotech has given the industry a powerful answer: a global reorder rate of over 90%.
In recent years, probiotics have shifted from a trend to a lifestyle essential. Their benefits for gut and overall health are no longer a niche topic — they’re a global movement. By 2030, the probiotics market is projected to exceed USD 100.1 billion. And in this wave of expansion, Glac Biotech has been quietly but steadily widening its footprint.
At home in Taiwan, Glac has secured partnerships with top brands. Abroad, the company has gone further — signing a strategic cooperation agreement with a leading South Korean health brand, while European and American raw material giants have rushed to secure exclusive distribution rights. Today, Glac’s probiotics reach nearly 30 countries worldwide. This isn’t just growth; it’s sustainable momentum.

Spotting Key Trends, Driving Consistent Growth
Why has Glac Biotech’s revenue grown 20% year after year, with overseas clients doubling in the past year? The answer lies in its long-term commitment: focusing resources on functional probiotic science and investing tens of millions in R&D, turning each “benefit claim” into hard, verifiable evidence.

Post-Pandemic Demand, Backed by 153 Global Patents
As global health awareness surged after the pandemic, Glac doubled down on science:

• 153 global patents spanning gut health, immune modulation, bowel regulation, and anti-aging.
• Star strains continually advancing through single-strain clinical trials and publications in international journals:
  • L. rhamnosus MP108
  • B. animalis subsp. lactis CP-9
  • L. rhamnosus F-1

This level of validation not only supports consumer trust but also cements Glac’s depth of expertise in the probiotics field.

170+ Scientific Publications, 3,200+ Clinical Cases
Glac’s research team has invested years into building evidence. To date, they’ve:

• Published over 170 scientific papers in international journals.
• Conducted 40 clinical trials, involving more than 3,200 participants.

These results provide solid backing for the stability, safety, and efficacy of Glac’s probiotics and postbiotics, giving OEM partners confidence that every product built with Glac ingredients can deliver.

Awards That Speak Louder Than Words
Recognition has followed achievement. Glac’s flagship strains have taken home some of the world’s most prestigious awards:

• B. lactis CP-9: Winner of the NutraIngredients Award in the Body Management category.
• Totipro® PE0401 Postbiotic: Winner of the Microbiome Modulation Award, the first postbiotic to achieve this honor.

These accolades don’t just affirm Glac’s leadership — they bring global attention to Taiwan’s probiotics industry as a whole.

Breaking New Ground: PRONULIFE® LvUCare Wins Innovation Award
Adding to the momentum, Glac’s PRONULIFE® LvUCare, designed for people with liver and high uric acid concerns, recently won the Lactic Acid Bacteria Association’s Innovation Award. Developed to address conditions often linked to modern lifestyles — from high blood sugar and cholesterol to hypertension and hyperuricemia — LvUCare takes a unique approach by regulating gut microecology to generate liver health benefits. This breakthrough highlights Glac’s ability to anticipate unmet health needs and innovate accordingly.

Scaling Up for 2024: New Hsinchu Plant Expands Capacity 5x
With demand surging, Glac is preparing its next leap: the launch of a new Hsinchu plant in 2024.

• Capacity expansion by 5x (with potential to grow up to 8x).
• Facility size increased from 2,000 to 3,000 ping.
• Upgraded, fully automated production lines.

The new plant will leverage Glac’s proprietary PRONEX® production process and PRIMETEK® OEM technologies, further strengthening its ability to meet large-scale, standardized global orders with world-class precision.

International Recognition of Postbiotics & Global Expansion
Glac’s PRONULIFE® series and Totipro® postbiotics have already been showcased at major global events — Vitafoods Europe, Vitafoods Asia (Thailand), SupplySide West (USA), and Fi Europe (Germany). Each time, they’ve captured the attention of international ingredient leaders and sparked lively discussions about postbiotics’ future.
Today, Glac has already developed 15 functional probiotic applications, ensuring its offerings meet the evolving needs of corporate clients worldwide. And the innovation won’t stop here.

Looking Ahead
Glac Biotech closed 2023 with projected revenue of NT$380 million, a growth rate of over 30% year-on-year. With the new plant’s launch in 2024, revenues are expected to double with sustained double-digit growth.
After 15 years of deep industry experience, Glac continues to stand out as one of the most reliable champions in probiotics. Its formula for success is clear: science-backed validation, uncompromising production standards, and continuous innovation.
As the world steps into 2024, Glac is not just ready to compete — it’s ready to lead, shaping the future of probiotics and postbiotics for consumers everywhere.
 

Media Coverage (Extended Reading)

• Aotter NetNews — Dec 28, 2023 (Chinese)
  https://nb.aotter.net/post/658d09ec8f9fe85fa234014c